Check-Cap (NASDAQ:CHEK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Check-Cap (NASDAQ:CHEK) to a hold rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Check-Cap Stock Performance

Shares of NASDAQ CHEK opened at $1.86 on Friday. Check-Cap has a 52-week low of $0.56 and a 52-week high of $3.13. The firm has a market capitalization of $10.88 million, a price-to-earnings ratio of -0.67 and a beta of 0.41. The stock has a 50 day moving average price of $1.79 and a 200 day moving average price of $1.13.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.